Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+9.0%
Amgen logo
AmgenAMGN
$1.82B+5.1%
Gilead Sciences logo
Gilead SciencesGILD
$2.02B+53.7%
Replimune Group logo
Replimune GroupREPL
-$70.93M-6.9%
CG Oncology logo
CG OncologyCGON
-$60.2M-74.7%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.09M-122%

Other financials

Income statement

See full
Revenue$31.0K0.0%
Operating income-$16.3M-100%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$693.87M+192%
Enterprise value$501.88M+220%
P/S5,595.7×-18,674×

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp
FCF margin-26,383.9%+14,851pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s net income?
Candel Therapeutics, Inc. (CADL) reported net income of -$8.86M in Q1 2026.
How has Candel Therapeutics, Inc.'s net income changed year-over-year?
Candel Therapeutics, Inc.'s net income decreased by 220.1% year-over-year, from $7.38M to -$8.86M.
What is the long-term trend for Candel Therapeutics, Inc.'s net income?
Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s net income has grown at a 0.3% compound annual growth rate (CAGR), from -$37.72M to -$38.18M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.